Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27264586 | 0.91 | PIK3CD (0.34) | POLBEPHX1SMN1; SMN2PIK3CDTSHR | |
| SCHEMBL25620919 | 0.87 | PIK3CD (0.34) | POLBEPHX1PIK3CDTSHR | |
| SCHEMBL19227414 | 0.83 | POLB (0.42) | POLBEPHX1HTTSMN1; SMN2MAPT | |
| SCHEMBL19245616 | 0.83 | DPP4 (0.32) | POLBPIK3CDTSHRDPP4 | |
| SCHEMBL20143695 | 0.83 | TSHR (0.33) | POLBSMN1; SMN2PIK3CDTSHRALDH1A1 | |
| SCHEMBL27264484 | 0.83 | POLB (0.31) | POLBPIK3CDTSHR | |
| SCHEMBL23818386 | 0.81 | EPHX1 (0.32) | POLBEPHX1 | |
| SCHEMBL8279457 | 0.81 | POLB (0.41) | POLBEPHX1HTTSMN1; SMN2MEN1 | |
| SCHEMBL19750459 | 0.79 | POLB (0.40) | POLBEPHX1HTTSMN1; SMN2MAPT | |
| SCHEMBL12327891 | 0.79 | POLB (0.40) | POLBEPHX1HTTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-2738190-B1 | AMPHIPHILIC MACROMOLECULE AND USE | BEIJING JUNLUN RUNZHONG SCIENCE&TECHNOLOGY CO LTD (CN) | 2017-08-09 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-4137304-A | TOPICAL OR ORAL ADMINISTERED TOBACCO PRODUCT | WILKINSON SWORD LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137305-A | TOBACCO | WILKINSON SWORD LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4136164-A | FOR USE IN FOODS, TOPICAL PREPARATIONS, AND TOBACCO | WILKINSON SWORD LIMITED (GB) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | POLB 889/4885EPHX1 756/4885HTT 3496/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | POLB 889/4885EPHX1 756/4885HTT 3496/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | POLB 3304/4885EPHX1 664/4885HTT 2071/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | POLB 3304/4885EPHX1 664/4885HTT 2071/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | POLB 2879/4885EPHX1 1834/4885HTT 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.